Which peptides are studied for infections?

Short answer

6 profiles here are grouped under “Infections”: 3 FDA-approved, 1 in clinical trials and 2 not FDA-approved.

Each entry below quotes its profile and links to the full answer there.

FDA-approved 3

In clinical trials 1

Not FDA-approved 2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Drugs@FDA: DALVANCE (dalbavancin hydrochloride), NDA 021883 · original approval May 23, 2014 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  2. 2
    DALVANCE (dalbavancin) for injection · SPL version 29 · published 2025-11-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  3. 3
    CUBICIN RF (daptomycin) injection, powder, lyophilized, for solution · SPL version 22 · published 2025-06-20 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  4. 4
    Drugs@FDA: CUBICIN and CUBICIN RF (daptomycin), NDA 021572 · original approval September 12, 2003 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  5. 5
    Drugs@FDA: FUZEON (enfuvirtide), NDA 021481 · original approval March 13, 2003 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  6. 6
    Aviptadil substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  7. 7
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial (2023) · PMID 37348524 ↗

    The Lancet Respiratory Medicine · Official source · Source checked November 15, 2026

  9. 9
    Thymopentin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  10. 10
    FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  11. 11
    December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026